A researcher reviewing printed clinical trial charts

· updated

503A vs 503B Compounding: What It Means for Peptides


503A and 503B are the two legal lanes for compounded drugs in the US, and every peptide headline this year runs through one of them. A 503A pharmacy is the traditional kind: it makes a drug for one named patient from a valid prescription. A 503B “outsourcing facility” works more like a small manufacturer: it follows factory-grade quality rules, gets inspected by the FDA, and can ship to clinics without a patient name attached. The good news for anyone following BPC-157 and friends is that the legit path is getting clearer, and as of October 2026 it runs through 503A.

Key facts

What is a 503A pharmacy?

Think of your local compounding pharmacy. Under section 503A of the Food, Drug, and Cosmetic Act, a state-licensed pharmacist or physician can prepare a custom drug, but the FDA says one of the conditions is that “the drugs must be compounded based on the receipt of valid patient-specific prescriptions.” No prescription with your name on it, no compounded drug.

The raw ingredient (the FDA calls it a “bulk drug substance”) also has to qualify. Under 503A it must meet one of three conditions:

  1. It complies with a USP or NF monograph (an official quality standard), if one exists.
  2. It is a component of an FDA-approved drug, if there is no monograph.
  3. It appears on the FDA’s 503A Bulks List.

Most of the peptides people talk about at the gym have no monograph and are not in any approved drug. So for them, option 3 is the whole ballgame. That is why the Bulks List keeps showing up in the news. One exception worth knowing: sermorelin qualifies through option 2 because of its old FDA approval, which we break down in our sermorelin 503A explainer.

What is a 503B outsourcing facility?

503B was added in 2013 as a voluntary category. Facilities that sign up take on more rules in exchange for more reach. Per the FDA, “unlike compounders operating under section 503A, outsourcing facilities are subject to CGMP requirements,” the same quality system drug makers follow. They are inspected by the FDA on a risk-based schedule and must report adverse events and tell the FDA what they make.

In return, a 503B facility can fill an order from a hospital or clinic that is “not for an identified individual patient (e.g., for office stock).” That is how a clinic can have a compounded product on the shelf before a patient walks in.

The ingredient rules are different too. A 503B facility can only use a bulk substance if it is on the 503B bulks list, which is reserved for substances with “a clinical need,” or if the finished drug is on the FDA’s drug shortage list at the time of compounding. Shortage is the reason compounded semaglutide and tirzepatide were widely available for a while, a story we cover in compounded vs brand-name semaglutide.

503A vs 503B at a glance

503A pharmacy 503B outsourcing facility
Who it serves One named patient Patients or clinics (office stock)
Prescription Required, patient-specific Not always tied to one patient
Quality rules Exempt from CGMP Must follow CGMP
FDA inspection Not described on FDA’s page Risk-based FDA schedule
Ingredient path Monograph, approved-drug component, or 503A Bulks List 503B bulks list (clinical need) or drug shortage

What are Category 1 and Category 2?

While the FDA works through nominated ingredients, it sorts them into three buckets. Category 1 substances “may be eligible for inclusion,” and under its interim policy the FDA “does not intend to take action against a compounder” using them if the conditions are met. Category 2 is for substances where the FDA “has identified significant safety risks,” and compounders using them risk enforcement. Category 3 means the nomination lacked enough information. There is a separate set of categories for 503B. One more detail: the FDA says it does not intend to place substances nominated on or after Jan 7, 2025 into these categories.

Why the peptide vote is about 503A

The July 2026 advisory committee voted on the 503A Bulks List specifically. FDA staff had recommended against all seven peptides, calling the available studies “short in duration, small in sample size, and insufficient to establish safety or effectiveness.” The panel went the other way on six of them; emideltide (DSIP) was rejected 7-6. Full breakdown in our PCAC vote results.

If the FDA adopts those recommendations, the path would be a 503A one: a provider writes a prescription for a specific patient, and a licensed compounding pharmacy prepares it. Law firm Holland & Knight notes the FDA “is not obligated to follow the PCAC recommendations but often does,” and that the change has to go through notice-and-comment rulemaking. Past 503A rulemaking has not been fast: a February 2019 final rule placed six substances on the list, and for a September 2019 proposal to add five more, the FDA’s page (updated May 14, 2026) still says a final regulation will come after it considers comments.

What the October report could change

Update, Oct 30, 2026: HHS has now filed the policy, covering six peptides and excluding 503B outsourcing facilities. See what the HHS policy says. The rest of this section is kept as written.

The Oct 7 report describes a stopgap: certain previously restricted peptides could be sold temporarily through compounding pharmacies while the FDA writes the rules. Officials are reportedly discussing guardrails such as patient disclosures, adverse-event reporting and data collection. Supporters frame it as moving demand from the gray market into regulated pharmacies.

The honest caveats: the plan had not been formally announced as of Oct 8, it could still change, and the coverage we read does not name the seven peptides. FDA career scientists said in late June that the evidence was too weak to support compounding them. Access and proof are different things, and none of these peptides is FDA-approved. Our BPC-157 evidence review shows how thin the human data still is.

What it means for you

If a compounded peptide reaches you legitimately, it will almost certainly come with a prescription from a licensed provider and a 503A pharmacy label with your name on it. A product with no prescription, no pharmacy and a “not for human use” label is outside both lanes, whatever the news says. Payers generally treat compounded drugs as outside standard pharmacy coverage, so expect cash prices even after a final rule. If a peptide is on your radar, talk to a licensed provider, follow the live legal status tracker for changes, and see how peptides get prescribed.

Sources

Educational content only, not medical advice or legal advice. Talk to a licensed provider about whether any medicine is right for you.

← All articles